DarioHealth Corp. Implements a 20-for-1 Reverse Stock Split
DarioHealth Corp. (NASDAQ: DRIO), recognized as a pioneer in the digital health sphere, has revealed an important strategic move this year. The company has announced a reverse stock split, consolidating shares at a 20-for-1 ratio. This action is anticipated to take effect at the opening of the market.
Understanding the Reverse Stock Split
The reverse stock split means that for every twenty shares a shareholder owns, they will receive one share in return. After instituting this split, DarioHealth's total outstanding common stock will decrease drastically, reducing from approximately 47.99 million shares to about 2.40 million shares. However, it’s important to note that the number of authorized shares remains unchanged at 400 million.
Impact on Shareholders
This move is intended to enhance the stock's market presence and improve overall trading conditions. Despite the reduction in the number of outstanding shares, the reverse stock split will not impact shareholders' proportional ownership or voting power in DarioHealth. Any resulting fractional shares from this split will be rounded up and rounded to the nearest whole number for individual stockholders.
Reasons Behind the Split
The DarioHealth board of directors approved the reverse stock split to align with its strategic goals and enhance the company's visibility in the market. Such consolidations are often employed by companies seeking to bolster their stock prices and attract institutional investors who may impose minimum share price thresholds.
Post-Split Trading Dynamics
After the reverse stock split, DarioHealth's shares will continue to be traded under the existing ticker symbol "DRIO" on the Nasdaq Capital Market. However, shareholders will notice a new CUSIP Number for the post-split shares. This structural change aims at providing a better trading experience and potential for stock price appreciation.
Adjustment of Securities
In addition to the common stock adjustments, other securities linked to DarioHealth, such as stock options, convertible securities, and warrants, will also undergo appropriate modifications in accordance with the split. This ensures fairness in the adjustment process for all shareholders regardless of their investment types.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is at the forefront of digital health innovation, transforming how individuals with chronic conditions manage their well-being. This platform offers dynamic, personalized therapeutic solutions that harness data analytics coupled with one-on-one coaching. DarioHealth effectively addresses critical health issues such as diabetes, hypertension, behavioral health, and weight management.
The platform is designed to be user-centric, making healthcare more accessible and manageable for individuals. Through personalized interventions and solutions, DarioHealth empowers users to make sustainable lifestyle changes with visible results that enhance their health journey.
Contact Information
DarioHealth encourages its investors and stakeholders to reach out for further inquiries. For questions or additional insights, please connect with:
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Frequently Asked Questions
What is a reverse stock split?
A reverse stock split consolidates the number of existing shares into fewer ones, helping companies increase their stock price for trading purposes.
How will the reverse stock split affect my shares?
After the split, for every 20 shares you own, you will effectively hold 1 share, but the total value of your investment should remain the same.
When will the reverse stock split take effect?
DarioHealth's reverse stock split is expected to be implemented at market open.
Will the number of authorized shares change?
No, the authorized shares remain unchanged at 400 million, even after the reverse stock split occurs.
Who can I contact for more information?
You can reach out to DarioHealth's Investor Relations via the provided contact emails for any further inquiries.
